Myxedema coma following rifampicin - A clinical case and literature review

Ann Endocrinol (Paris). 2023 Feb;84(1):81-82. doi: 10.1016/j.ando.2022.09.019. Epub 2022 Sep 29.

Authors

Miguel Saraiva¹, Ariana Maia², Guilherme Assunção², Cláudia Freitas², André Couto de Carvalho²

Affiliations

¹ Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário do Porto, Largo do Prof. Abel Salazar, Porto 4099-001, Portugal. Electronic address: miguelsaraiva.md@gmail.com.
² Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário do Porto, Largo do Prof. Abel Salazar, Porto 4099-001, Portugal.

PMID: 36371351
DOI: 10.1016/j.ando.2022.09.019

No abstract available

Publication types

Review
Letter

MeSH terms

Coma / chemically induced
Humans
Myxedema* / chemically induced
Myxedema* / drug therapy
Rifampin / adverse effects
Thyroxine / therapeutic use

Substances

Rifampin
Thyroxine